Hrain anti-BCMA CAR-T vs Zevorcabtagene autoleucel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

Hrain anti-BCMA CAR-T

Developed by Hrain Biotechnology Co., Ltd.

Phase 2 in Multiple Myelomacell therapy (autologous BCMA-targeted CAR-T)
Weak signal

NCT03093168 · Phase 1 · status unknown

This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The published five-year analysis reports 49 treated patients, more than this study's originally listed enrollment.

Reported efficacy

Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0 (6 months): ORR 77.55% (38/49 patients); sCR 24.49% (12 patients), CR 24.49% (12 patients); median PFS 9.5 months (95% CI 5.01-13.99), median OS 20.0 months (95% CI 11.26-28.74)

Result source: NCT03093168

Zevorcabtagene autoleucel

Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners

Phase 1/2 in Multiple Myelomacell therapy (autologous BCMA-targeted CAR-T)
Weak signal

NCT03975907 · Phase 1/2 · status unknown

This study enrolled every patient into a single treatment group, with no comparison arm and no blinding, so there is no control group to judge the response rate against. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The registered phase 1 primary endpoint of this study is dose-limiting toxicity; the response rates shown are the phase 2 portion's primary endpoint (overall response rate).

Reported efficacy

Phase 1, Safety and tolerability: dose limiting toxicity (28days post administration of CAR-T-cells); Phase 2, efficacy of CT053 CAR-BCMA T cells: overall response rate (3 months post administration of CAR-T-cells): LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR). (met)

Result source: NCT03975907

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHrain anti-BCMA CAR-TZevorcabtagene autoleucel
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

Hrain anti-BCMA CAR-T
—Not reported
Zevorcabtagene autoleucel
—Not reported

OS, median

Hrain anti-BCMA CAR-T
—Not reported
Zevorcabtagene autoleucel
—Not reported

ORR

Hrain anti-BCMA CAR-T
—Not reported
Zevorcabtagene autoleucel
—Not reported

VGPR or better

Hrain anti-BCMA CAR-T
—Not reported
Zevorcabtagene autoleucel
—Not reported

MRD negativity

Hrain anti-BCMA CAR-T
—Not reported
Zevorcabtagene autoleucel
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Hrain anti-BCMA CAR-T: no structured comparison results are available for Multiple Myeloma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Zevorcabtagene autoleucel
LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR). NCT03975907 · Phase 1/2 · design grade: weak · publication or press release
LUMMICAR STUDY 2 (NCT03915184): objective response rate 100% in evaluable relapsed/refractory multiple myeloma patients. NCT03915184 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hrain anti-BCMA CAR-T's landscape · Zevorcabtagene autoleucel's landscape